FY2026 EPS Estimates for argenx SE Raised by HC Wainwright (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGXGet Rating) – Investment analysts at HC Wainwright lifted their FY2026 earnings estimates for shares of argenx in a research note issued on Tuesday, January 10th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $62.29 per share for the year, up from their previous estimate of $60.34. HC Wainwright currently has a “Buy” rating and a $480.00 target price on the stock. The consensus estimate for argenx’s current full-year earnings is ($15.54) per share.

Several other brokerages have also recently weighed in on ARGX. Wells Fargo & Company upped their price target on shares of argenx from $461.00 to $469.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 18th. Deutsche Bank Aktiengesellschaft increased their target price on shares of argenx from €400.00 ($430.11) to €425.00 ($456.99) and gave the company a “buy” rating in a research report on Thursday, September 22nd. SVB Leerink increased their target price on shares of argenx from $428.00 to $430.00 and gave the company an “outperform” rating in a research report on Friday, October 28th. Evercore ISI raised shares of argenx to an “outperform” rating in a research report on Friday, October 21st. Finally, JPMorgan Chase & Co. increased their target price on shares of argenx from €470.00 ($505.38) to €480.00 ($516.13) and gave the company an “overweight” rating in a research report on Monday, November 14th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $452.83.

argenx Stock Performance

Shares of ARGX opened at $403.65 on Thursday. The company has a 50 day moving average price of $378.69 and a 200-day moving average price of $373.01. argenx has a fifty-two week low of $249.50 and a fifty-two week high of $407.93. The stock has a market capitalization of $22.33 billion, a PE ratio of -23.48 and a beta of 0.80.

argenx (NASDAQ:ARGXGet Rating) last announced its quarterly earnings results on Thursday, October 27th. The company reported ($4.26) earnings per share for the quarter, missing the consensus estimate of ($3.50) by ($0.76). argenx had a negative return on equity of 49.53% and a negative net margin of 295.08%. The business had revenue of $146.49 million during the quarter, compared to analysts’ expectations of $115.49 million.

Institutional Trading of argenx

Hedge funds and other institutional investors have recently made changes to their positions in the business. Comerica Bank increased its stake in shares of argenx by 5.0% in the second quarter. Comerica Bank now owns 874 shares of the company’s stock worth $326,000 after acquiring an additional 42 shares during the period. Chartwell Investment Partners LLC acquired a new stake in shares of argenx in the second quarter worth $594,000. Crossmark Global Holdings Inc. grew its position in argenx by 2.1% during the second quarter. Crossmark Global Holdings Inc. now owns 5,722 shares of the company’s stock valued at $2,168,000 after buying an additional 115 shares during the period. Urban Wealth Management LLC acquired a new stake in argenx during the second quarter valued at $64,000. Finally, Eqis Capital Management Inc. acquired a new stake in argenx during the third quarter valued at $1,177,000. Institutional investors and hedge funds own 57.29% of the company’s stock.

About argenx

(Get Rating)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.

Featured Articles

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.